Back grey_arrow_rt.gif
US commits an additional $884 million for influenza A (H1N1) vaccine
  July 13, 2009
by Mark Todoruk

The US Department of Health and Human Services announced Monday that it will spend a further $884 million to buy ingredients to produce a potential vaccine against the influenza A (H1N1) virus. The HHS explained that "the funds will be used to place additional orders for bulk H1N1 antigen and adjuvant on existing contracts" with Novartis, GlaxoSmithKline, AstraZeneca, and sanofi-aventis.

The latest orders are valued at approximately $690 million for Novartis, $71.4 million for GlaxoSmithKline, $61.4 million for sanofi-aventis, and $61 million for AstraZeneca. HHS Secretary Kathleen Sebelius remarked that the ingredients are being acquired "to further prepare the nation for a potential resurgence of the 2009 H1N1 virus," and she stated that "the action we are taking today will provide flexibility in a future immunisation programme, if a programme is recommended."

The news follows a previous announcement by the HHS in May that it was committing nearly $1 billion to develop a vaccine and to conduct clinical studies on potential vaccines.

Reference Articles

US to spend $884 million more on swine flu vaccine - (Forbes)

HHS purchases additional H1N1 vaccine ingredients - (HHS)

US to buy H1N1 vaccine components from four firms - (The Wall Street Journal)

MedImmune gets second H1N1 flu contract - (Washington Business Journal)

  icon paper stack View Older Articles   Back to Top